601607 上海医药
2025/12 -
人民幣(K¥)

变动
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入283,579,6013.03%260,295,089231,981,300215,824,259191,909,156
减:营业总成本276,283,4773.22%253,008,864224,907,251209,641,475185,559,849
    其中:营业成本253,163,1213.49%228,966,947201,494,923187,281,149165,180,104
               财务费用1,407,224-4.98%1,485,7581,313,1921,245,3691,239,584
               资产减值损失(1,018,556)65.79%(561,277)(331,471)(140,441)(898,616)
公允价值变动收益332,12162.92%404,731218,738(206,004)116,798
投资收益3,170,144733.31%(68,123)533,1171,811,394976,195
    其中:对联营企业和合营企业的投资收益284,473-45.49%129,329526,743789,5961,009,547
营业利润9,942,08622.13%7,667,2359,014,6508,205,4867,184,388
利润总额9,819,80522.44%7,054,2978,808,3538,143,8157,175,483
减:所得税费用2,846,08732.38%1,887,7261,816,3391,869,2451,570,219
净利润6,973,71818.80%5,166,5706,992,0156,274,5695,605,264
减:非控股权益1,249,160-5.19%1,398,5711,374,8631,181,1021,109,047
股东净利润5,724,55825.74%3,768,0005,617,1525,093,4674,496,217

市场价值指针
每股收益 (元) *1.54025.20%1.0201.6101.7901.580
每股派息 (元) *0.47027.03%0.4100.6100.4200.480
每股净资产 (元) *20.4655.87%18.50018.13717.36715.958
审计意见 #标准无保留意见标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容